GeneHealth - Your precision medicine

Dermatitis Herpetiformis

Disease Details

Family Health Simplified

Buy Membership

Description: Dermatitis herpetiformis is a chronic skin condition characterized by intensely itchy, blistering skin eruptions, often associated with gluten sensitivity.
Type: Dermatitis herpetiformis is an autoimmune disease. It is associated with a genetic predisposition linked to the presence of specific human leukocyte antigen (HLA) genes, particularly HLA-DQ2 and HLA-DQ8, which are also linked to celiac disease. The genetic transmission is thus influenced by these genetic markers, making it familial but not following a clear Mendelian inheritance pattern.
Signs And Symptoms: Dermatitis herpetiformis is characterized by intensely itchy, chronic papulovesicular eruptions, usually distributed symmetrically on extensor surfaces (buttocks, back of neck, scalp, elbows, knees, back, hairline, groin, or face).: 616 The blisters vary in size from very small up to 1 cm across. The condition is extremely itchy, and the desire to scratch may be overwhelming. This sometimes causes the affected person to scratch the blisters off before they are examined by a physician. Intense itching or burning sensations are sometimes felt before the blisters appear in a particular area.The signs and symptoms of DH typically appear around 30 to 40 years of age, although all ages may be affected. Although the first signs and symptoms of dermatitis herpetiformis are intense itching and burning, the first visible signs are the small papules or vesicles that usually look like red bumps or blisters. The rash rarely occurs on other mucous membranes, except the mouth or lips. The symptoms range in severity from mild to serious, but they are likely to disappear if gluten ingestion is avoided and appropriate treatment is administered.
Dermatitis herpetiformis symptoms are chronic, and they tend to come and go, mostly in short periods of time in response to the amount of gluten ingested. Sometimes, these symptoms may be accompanied by symptoms of coeliac disease, which typically include abdominal pain, bloating or loose stool, weight loss, and fatigue. However, individuals with DH often have no gastrointestinal symptoms even if they have associated intestinal damage.The rash caused by dermatitis herpetiformis forms and disappears in three stages. In the first stage, the patient may notice a slight discoloration of the skin at the site where the lesions appear. In the next stage, the skin lesions transform into obvious vesicles and papules that are likely to occur in groups. Healing of the lesions is the last stage of the development of the symptoms, usually characterized by a change in skin color. This may result in areas of the skin turning darker or lighter than the color of the skin on the rest of the body. Because of the intense itching, patients usually scratch, which may lead to the formation of crusts.
Prognosis: Dermatitis herpetiformis generally responds well to medication and a strict gluten-free diet. It is an autoimmune disease, however, and thus individuals with DH are more likely to develop other autoimmune conditions such as thyroid disease, insulin-dependent diabetes, lupus erythematosus, Sjögren's syndrome, sarcoidosis, vitiligo, and alopecia areata. There has been an association of non-Hodgkin lymphoma in individuals who have dermatitis herpetiformis, although this risk decreases to less than the population risk with a strict gluten-free diet.Dermatitis herpetiformis does not usually cause complications on its own, without being associated with another condition. Complications from this condition, however, arise from the autoimmune character of the disease, as an overreacting immune system is a sign that something does not work well and might cause problems to other parts of the body that do not necessarily involve the digestive system.Gluten intolerance and the body's reaction to it make the disease more worrying in what concerns the possible complications. This means that complications that may arise from dermatitis herpetiformis are the same as those resulting from coeliac disease, which include osteoporosis, certain kinds of gut cancer, and an increased risk of other autoimmune diseases such as thyroid disease.
The risks of developing complications from dermatitis herpetiformis decrease significantly if the affected individuals follow a gluten-free diet.
Onset: Dermatitis herpetiformis typically has an onset in young adulthood, most commonly between the ages of 20 and 40.
Prevalence: Dermatitis herpetiformis (DH) is a rare chronic skin condition that is associated with celiac disease. The prevalence of DH varies by population but is estimated to be approximately 1 in 10,000 people worldwide. It is more common in people of Northern European descent and less common in those of Asian and African descent.
Epidemiology: Global estimates of the prevalence of dermatitis herpetiformis range from 1 in 400 to 1 in 10,000 people. Individuals of Northern European descent are most likely to be affected and estimates of the rates of DH in British and Finnish populations range from 30 in 100,000 to 75 in 100,000 people, respectively. The annual incidence rate of DH in these populations range from 0.8 to 2.7 per 100,000.People of all ages may be affected, although the mean age at diagnosis varies between 30 and 40 years of age. There is a slight male predominance in DH for unknown reasons and it is associated with celiac disease and the haplotypes HLA-DQ2 and, less commonly, HLA-DQ8.
Intractability: Dermatitis herpetiformis is a chronic condition that can be managed effectively but is often considered intractable because it tends to persist over time. Treatment usually involves a strict gluten-free diet and medications like dapsone to control symptoms. While symptoms can be controlled, the condition itself typically requires ongoing management and does not usually resolve completely on its own.
Disease Severity: Dermatitis herpetiformis is a chronic skin condition characterized by intensely itchy and blistering skin eruptions, predominantly found on the elbows, knees, buttocks, and back. The severity of the disease can vary among individuals; some may experience mild symptoms, while others suffer from severe itching and discomfort. The condition is often associated with celiac disease and typically responds well to a gluten-free diet and medications like dapsone.
Healthcare Professionals: Disease Ontology ID - DOID:8505
Pathophysiology: In terms of pathology, the first signs of the condition may be observed within the dermis. The changes that may take place at this level may include edema, vascular dilatation, and cellular infiltration. It is common for lymphocytes and eosinophils to be seen. The bullae found in the skin affected by dermatitis herpetiformis are subepidermal and have rounded lateral borders.
When looked at under the microscope, the skin affected by dermatitis herpetiformis presents a collection of neutrophils. They have an increased prevalence in the areas where the dermis is closest to the epidermis.
Direct IMF studies of uninvolved skin show IgA in the dermal papillae and patchy granular IgA along the basement membrane. The jejunal mucosa may show partial villous atrophy, but the changes tend to be milder than in coeliac disease.Immunological studies revealed findings that are similar to those of coeliac disease in terms of autoantigens. The main autoantigen of dermatitis herpetiformis is epidermal transglutaminase (eTG), a cytosolic enzyme involved in cell envelope formation during keratinocyte differentiation.Various research studies have pointed out different potential factors that may play a larger or smaller role in the development of dermatitis herpetiformis. The fact that eTG has been found in precipitates of skin-bound IgA from skin affected by this condition has been used to conclude that dermatitis herpetiformis may be caused by a deposition of both IgA and eTG within the dermis. It is estimated that these deposits may resorb after ten years of following a gluten-free diet. Moreover, it is suggested that this condition is closely linked to genetics. This theory is based on the arguments that individuals with a family history of gluten sensitivity who still consume foods containing gluten are more likely to develop the condition as a result of the formation of antibodies to gluten. These antibodies cross-react with eTG, and IgA/eTG complexes deposit within the papillary dermis to cause the lesions of dermatitis herpetiformis. These IgA deposits may disappear after long-term (up to ten years) avoidance of dietary gluten.Gliadin proteins in gluten are absorbed by the gut and enter the lamina propria where they need to be deamidated by tissue transglutaminase (tTG). tTG modifies gliadin into a more immunogenic peptide. Classical dendritic cells (cDCs) endocytose the immunogenic peptide and if their pattern recognition receptors (PRRs) are stimulated by pathogen-associated molecular patterns (PAMPs) or danger-associated molecular pattern (DAMPs), the danger signal will influence them to secrete IL-8 (CXCL8) in the lamina propria, recruiting neutrophils. Neutrophil recruitment results in a very rapid onset of inflammation. Therefore, co-infection with microbes that carry PAMPs may be necessary for the initial onset of symptoms in gluten sensitivity, but would not be necessary for successive encounters with gluten due to the production of memory B and memory T cells (discussed below).
Dermatitis herpetiformis may be characterised based on inflammation in the skin and gut. Inflammation in the gut is similar to, and linked to, celiac disease. tTG is treated as an autoantigen, especially in people with certain HLA-DQ2 and HLA-DQ8 alleles and other gene variants that cause atopy. tTG is up-regulated after gluten absorption. cDCs endocytose tTG-modified gliadin complexes or modified gliadin alone but they only present gliadin to CD4+ T cells on pMHC-II complexes. These T cells become activated and polarised into type I helper T (Th1) cells. Th1 cells reactive towards gliadin have been discovered, but none against tTG. A naive B cell sequesters tTG-modified gliadin complexes from the surface of cDCs in the lymph nodes (LNs) before they become endocytosed by the cDCs. The B cell receptor (membrane bound antibody; BCR) is specific to the tTG portion of the complex. The B cell endocytoses the complex and presents the modified gliadin to the activated Th1 cell's T cell receptor (TCR) via pMHC-II in a process known as epitope spreading. Thus, the B cell presents the foreign peptide (modified gliadin) but produces antibodies specific for the self-antigen (tTG). Once the B cell becomes activated, it differentiates into plasma cells that secrete autoantibodies against tTG, which may be cross-reactive with epidermal transglutanimase (eTG). Class A antibodies (IgA) deposit in the gut. Some may bind to the CD89 (FcαRI) receptor on macrophages (M1) via their Fc region (constant region). This will trigger endocytosis of the tTG-IgA complex, resulting in the activation of macrophages. Macrophages secrete more IL-8, propagating the neutrophil-mediated inflammatory response.
The purportedly cross-reactive autoantibodies may migrate to the skin in dermatitis herpetiformis. IgA deposits may form if the antibodies cross-react with epidermal transglutanimase (eTG). Some patients have eTG-specific antibodies instead of tTG-specific cross-reactive antibodies and the relationship between dermatitis herpetiformis and celiac disease in these patients is not fully understood. Macrophages may be stimulated to secrete IL-8 by the same process as is seen in the gut, causing neutrophils to accumulate at sites of high eTG concentrations in the dermal papillae of the skin. Neutrophils produce pus in the dermal papillae, generating characteristic blisters. IL-31 accumulation at the blisters may intensify itching sensations. Memory B and T cells may become activated in the absence of PAMPs and DAMPs during successive encounters with tTG-modified gliadin complexes or modified gliadin alone, respectively. Symptoms of dermatitis herpetiformis are often resolved if patients avoid a gluten-rich diet.
Carrier Status: Dermatitis herpetiformis is not typically associated with a "carrier status" because it is not a communicable or directly inherited disease. Instead, it is considered an autoimmune condition strongly linked to celiac disease and associated with gluten sensitivity. Genetic predisposition, particularly the presence of certain HLA-DQ2 or HLA-DQ8 genes, plays a significant role in its development. However, having these genes does not mean one "carries" the disease in the way one might carry a pathogen or a single-gene mutation condition.
Mechanism: Dermatitis herpetiformis is an autoimmune blistering disorder strongly associated with celiac disease. The primary mechanism involves an abnormal immune response to gluten.

**Mechanism:**
1. **Gluten Sensitivity:** Ingestion of gluten (found in wheat, barley, and rye) leads to an immune response in genetically predisposed individuals.
2. **Immune Complex Formation:** Gluten peptides, once absorbed, are deamidated by the enzyme tissue transglutaminase (tTG). These deamidated peptides are then recognized by the immune system.
3. **Autoantibody Production:** This triggers the production of IgA antibodies against tTG and epidermal transglutaminase (eTG).
4. **Immune Complex Deposition:** These IgA antibodies form immune complexes that are deposited in the dermal papillae of the skin.
5. **Inflammatory Response:** The deposition of these immune complexes recruits neutrophils and other inflammatory cells, leading to complement activation and release of proteolytic enzymes.
6. **Blister Formation:** The enzyme releases and immune complex formation cause tissue damage and subepidermal blister formation characteristic of dermatitis herpetiformis.

**Molecular Mechanisms:**
1. **HLA-DQ2/DQ8 Genes:** Most patients with dermatitis herpetiformis have the HLA-DQ2 or HLA-DQ8 haplotypes, which increase the susceptibility to celiac disease and its cutaneous manifestation.
2. **Tissue Transglutaminase (tTG):** The intracellular enzyme modifies gluten peptides, enhancing their recognition by antigen-presenting cells.
3. **Epidermal Transglutaminase (eTG):** A close relative of tTG, eTG is the primary autoantigen targeted by IgA in dermatitis herpetiformis.
4. **IgA Deposition:** Circulating IgA antibodies specific to eTG bind to the basement membrane and dermal papillae, precipitating an immune response.
5. **Neutrophil Activation:** Neutrophils are attracted to the site of IgA deposition and release enzymes that disrupt the dermal-epidermal junction, causing blisters.

The condition is managed effectively by adhering to a strict gluten-free diet and, in some cases, using medications such as dapsone to control symptoms.
Treatment: **Treatment for Dermatitis Herpetiformis:**

1. **Dapsone:** An antibiotic that's effective in managing symptoms like itching and rash. It typically provides quick relief but requires regular blood monitoring due to potential side effects.

2. **Gluten-Free Diet:** As dermatitis herpetiformis is strongly associated with celiac disease, adhering to a strict gluten-free diet can help reduce symptoms and dependency on medications.

3. **Other Medications:** For individuals who cannot tolerate dapsone, other medications like sulfapyridine or tetracycline may be used.

4. **Symptom Management:** Topical corticosteroids and antihistamines may provide additional relief for itching and skin irritation.

Regular follow-ups with a healthcare provider are essential for managing the condition and monitoring for any potential complications.
Compassionate Use Treatment: Dermatitis herpetiformis is a chronic blistering skin condition linked to celiac disease. For those who do not respond to the primary treatment (a gluten-free diet and dapsone), some off-label or experimental treatments may include:

1. **Sulfapyridine or Sulfamethoxypyridazine:** These are alternative sulfa drugs that can be used if patients are intolerant to dapsone.
2. **Rituximab:** An off-label use; it is a monoclonal antibody that targets CD20 on B cells and has been used in refractory cases of dermatitis herpetiformis.
3. **Mycophenolate Mofetil:** Another off-label immunosuppressant that has shown effectiveness in some cases.
4. **Biologics:** Drugs such as etanercept (Enbrel) and infliximab (Remicade) are being explored in small studies for their efficacy in treating dermatitis herpetiformis.
5. **Topical Steroids:** While not curative, potent topical steroids are sometimes used for symptomatic relief.

Consultation with a healthcare provider specializing in dermatology or gastroenterology is essential for exploring these options.
Lifestyle Recommendations: For dermatitis herpetiformis, lifestyle recommendations include:

1. **Gluten-Free Diet**: Strictly adhering to a gluten-free diet can significantly reduce symptoms and is essential for managing the condition.
2. **Regular Medical Check-ups**: Regular follow-ups with a healthcare provider to monitor symptoms and nutritional status.
3. **Stress Management**: Incorporate stress-reducing techniques such as yoga, meditation, or regular exercise.
4. **Skin Care**: Use mild, fragrance-free soaps and moisturizers to avoid irritating the skin.
5. **Avoid Known Triggers**: Identify and avoid foods or substances that exacerbate symptoms.
6. **Proper Hydration**: Maintain adequate hydration to support overall skin health.
7. **Balanced Diet**: Ensure a balanced diet to prevent nutritional deficiencies, especially since a gluten-free diet may lack certain nutrients.

Consult with a healthcare provider or dietitian for personalized advice.
Medication: The primary medication used to treat dermatitis herpetiformis is dapsone, an antibiotic that helps control the rash and itching. Additionally, a gluten-free diet is often recommended as it can significantly reduce the symptoms and may decrease the need for medication.
Repurposable Drugs: For dermatitis herpetiformis, a chronic skin condition associated with celiac disease, repurposable drugs include:

1. Dapsone: An antibacterial medication that reduces inflammation and is effective in alleviating symptoms.
2. Sulfasalazine: Primarily used for inflammatory bowel disease, it may serve as an alternative for those intolerant to Dapsone.

Additionally, a strict gluten-free diet is crucial for managing both dermatitis herpetiformis and the underlying celiac disease. Consultation with a healthcare professional is essential for proper treatment and monitoring.
Metabolites: For dermatitis herpetiformis, there is no direct association with specific metabolites as primary markers. The condition is linked with gluten sensitivity and celiac disease. However, some metabolic changes may occur secondary to nutrient malabsorption, commonly seen in celiac disease such as deficiencies in various vitamins and minerals.

"Nan" typically stands for "Not a Number" in data-related contexts and doesn't apply to the clinical context of dermatitis herpetiformis. If you meant a different abbreviation or term, please clarify.
Nutraceuticals: For dermatitis herpetiformis, nutraceuticals are generally not the primary treatment. Instead, the primary approach involves a strict gluten-free diet, as this condition is closely associated with celiac disease. The most effective medical treatment is typically the antibiotic dapsone, which helps alleviate symptoms. Nutraceuticals have not been extensively studied for this condition, and their efficacy remains unclear.
Peptides: Dermatitis herpetiformis is a chronic skin condition associated with gluten sensitivity and is often linked to celiac disease. In individuals with dermatitis herpetiformis, ingestion of gluten leads to the formation of IgA antibodies, which form immune complexes with gluten-derived peptides. These deposits accumulate in the skin, particularly at the tips of the dermal papillae, initiating an inflammatory response that manifests as the characteristic itchy blisters and vesicles. The primary enzyme implicated in this process is tissue transglutaminase. Early diagnosis and a strict gluten-free diet are essential for managing the disease. If you need more information, please ask.